表紙
市場調查報告書

永久磁鐵馬達的全球市場

Permanent Magnet Motor

出版商 Global Industry Analysts, Inc. 商品編碼 957129
出版日期 內容資訊 英文 200 Pages
商品交期: 最快1-2個工作天內
價格
永久磁鐵馬達的全球市場 Permanent Magnet Motor
出版日期: 2020年09月01日內容資訊: 英文 200 Pages
簡介

全球永久磁鐵馬達的市場規模在2020年∼2027年的分析期間中預計將以7.5%的年複合成長率增長,從2020年的309億美元到2027年達到512億美元。本報告所分析市場區隔之一的永久磁鐵交流馬達 (PMAC) 部門在分析期間結束前預測將以7.8%的年率增長,達到220億美元的規模。

本報告提供全球永久磁鐵馬達市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Allied Motion Technologies, Inc.
  • Emerson Electric Company
  • General Electric Company
  • Johnson Electric Group
  • Nidec Corporation
  • Rockwell Automation, Inc.
  • Siemens AG
  • Toshiba Corporation
  • WEG SA
  • Yaskawa Electric Corporation

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • Covid-19的影響和即將到來的全球景氣衰退
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
  • 主要企業
  • 趨勢與成長要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:62公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP13927

On the Back of Falling Manufacturing Activity & Slumping Industrial Output, Demand for Permanent Magnet Motors Plummets by -11.6%.

The global market for Permanent Magnet Motors is expected to decline by -11.6% in the year 2020 and thereafter recover and grow to reach US$42.2 billion by the year 2027, trailing a post COVID-19 CAGR of 7.1%. COVID-19 has evolved from a biological phenomenon into a social and economic crisis. The pandemic is having a considerable impact on world economy and all industries. The asphyxiated economy has set into motion a cascading effect of a marked recession which is being felt by businesses and consumers alike. Global GDP is expected to dip into the red at -3% with the US economy shrinking by a shocking -5.9%. With roots in China, the world's supply chains are facing unprecedented disruption & shutdown. Interwoven with a demand crisis, the supply chain shocks are exerting a compounded blow to manufacturing companies worldwide. The worst affected industry in this pandemic driven crisis is manufacturing with its complex supply chains, labor intensive processes, and interdependencies. Division of labor, modular manufacturing strategies, outsourcing to reduce costs and increase the efficiency, consistency, and quality of each operations, have made the manufacturing sector most vulnerable amid the lockdown restrictions. An indication of the grim state of affairs is the fact that global manufacturing PMI is already declining and will fall to an estimated all-time low of 38.4 points in 2020 as compared to 53.8 in 2019. This indicates severe contraction of manufacturing activity including new orders, production, employment, supplier deliveries, inventories, customers' inventories, commodity prices, order backlog, new export orders, and imports. Global industrial output is plummeting sharply with the U.S posting steep declines of -16.5% & -15.2% in March & April 2020.

Business investment confidence is tumbling amidst poor demand, falling profits, liquidity crunch and a reeling global economy. The "great lockdown" of 2020 has crushed the global economy and with it the manufacturing sector. The loss in consumer confidence and erosion of household wealth and discretionary spending will impact virtually every industry and business worldwide. Global merchandize trade is expected to plummet by 15% to 30% in the year 2020 highlighting the magnitude of disruption. Against this backdrop, it requires very little speculation to measure the impact on manufacturing. In the United States alone over 80% of manufacturers are bracing for losses. The impact will mean crunch on capital resources; workforce layoffs/reduction and loss in productivity; supply chain disruptions; difficulties with funding; and increase in cybersecurity risks and fraud. Unlike IT services where work is being carried out remotely via internet and cloud platforms, for the manufacturing industry, plant activities and production cannot be carried remotely and therefore remains worst affected. The slower economic activity means reduced demand for industrial and consumer goods and lower manufacturing orders. In the midst of this crisis, demand for advanced materials used in manufacturing is taking a heavy blow as cash strapped companies struggle to cope. With manufacturing industry collapsing like a pack of cards, materials in the value chain are facing the biggest business setback ever. With wide ranging applications from automobiles, air conditioners, computer drives, conveyors, mixers, grinders, pumps, fans to blowers, permanent magnet motors (PMM) is worst affected. New waves of contagion sweeping through different countries, further decline in global trade and muted consumer spending make the return to growth scenario highly uncertain.

In the post COVID-19 period, demand recovery will be led by strong gains for AC type permanent magnet motors. The ideal features of permanent magnet AC motors such as high standard magnetic performance, faster accelerations, robust torque capacity, light weight and capacity to withstand overload electricity without magnetic loss, encourage wider adoption of these motors. Recent advances such as low field excitation losses and associated improvement in performance have made permanent magnet motors more efficient in terms of energy usage. The efficiency is further enhanced by superior power density, simple construction, electric durability and stability, and reliable performance. These factors are expected to drive the adoption of these motors in machinery tools and factory automation applications. Enhanced efficiency coupled with integration of these motors in electric vehicles and automobiles is poised to supplement market growth in future. The market will be bolstered by availability of material handling robots and strong focus on high precision. Permanent magnet motors are also slated to gain from increasing demand for chip conveyors, oil reservoirs, elevators, photocopy machines and coolant pumps across numerous industries. These motors will also witness robust demand from countries holding rare earth material resources. China commands the global rare earth magnet market and is the leading manufacturer of permanent magnet motors. The country scores high over other nations in terms of cost-competitiveness, and is slated to augment the market growth. The global market will also be driven by the increasing transition from induction towards permanent magnet motors to improve device performance and achieve energy savings.

Competitors identified in this market include, among others,

  • Allied Motion Technologies, Inc.
  • Emerson Electric Company
  • General Electric Company
  • Johnson Electric Group
  • Nidec Corporation
  • Rockwell Automation, Inc.
  • Siemens AG
  • Toshiba Corporation
  • WEG SA
  • Yaskawa Electric Corporation

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • A Prelude to Genetic Testing
    • Top Ten Genetic Diseases Worldwide
    • Different Types of Genetic Tests include
    • Prenatal and New-born Screening
    • Diagnostic Testing
    • Predictive & Presymptomatic Testing
    • Carrier Identification
    • Pharmacogenomic Testing
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Genetic Testing Delivery Models
    • Genetic Sequencing Approaches
    • Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Regain Momentum Post-COVID 19
    • Expanding Applications to Drive Genetic Testing Market
    • Regional Landscape
    • Prenatal Testing Market to Rise
    • Market Outlook
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
    • World Brands
    • Innovations
  • 3. MARKET TRENDS & DRIVERS
    • Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity
  • SEGMENT ANALYSIS
    • Prenatal Testing - Changing the World of Pregnancy Care
    • List of Available Prenatal Screening and Diagnostic Tests by Indication
    • Players in the Prenatal and New Born Genetic Testing Market
    • Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky Affair
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
    • Competition Intensifies in the NIPD Market
    • Select Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
    • Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
    • Predictive Diagnostics
    • Breast Cancer Gene Testing Market to Expand Strongly
    • Myriad Genetics - A Leader in Breast Cancer Testing
    • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
  • MARKET TRENDS AND GROWTH DRIVERS
    • Genetic Testing Paves the Way for Personalized Medicine
    • EXHIBIT 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medicine
    • Next-Generation Sequencing (NGS) - A Giant Leap in Genome Sequencing
    • Biomarker Discovery Leads to Advanced Genetic Testing
    • Select List of Available Tumour Markers
    • Immense Popularity of Ancestry Testing
    • Increasing Focus on Data Churning
    • Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
    • Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
    • Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
    • Hybrid Labs to Bridge Gap Between Traditional and DTC Models
    • Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
    • Emergence of Rapid DNA Testing
    • Oncology - A Key Focus Area for Genetic Testing
    • EXHIBIT 2: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Ageing Demographics to Drive Demand for Genetic Testing
    • EXHIBIT 3: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 2: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 3: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 5: World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 6: World 15-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 8: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 9: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 11: World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 12: World 15-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 14: World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 15: World 15-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 17: World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 18: World 15-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 21: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 23: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 24: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 26: World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 27: World 15-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 29: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 30: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Use of Genomic Data in Clinical Settings to Gather Pace
    • The United States: Leading Market for Genetic Testing Globally
    • Predictive Screening: Another Growth Area
    • Growing Relevance of Personalized Medicine Augurs Well
    • Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
    • EXHIBIT 4: Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Newborn Testing Gains Ground
    • Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
    • Coverage of NIPT in Average Risk Pregnancies Expands Target Market
    • Direct-to-Consumer Testing
    • Favourable Reimbursement Policies
    • Favourable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Demographic Changes Offer Growth Opportunities
    • EXHIBIT 5: North American Aging Population by Age Group: 1975-2050
    • Skepticism Limits Widespread Adoption of Genetic Testing
    • Competitive Overview
    • Myriad Eyes Diversification and Expansion for Growth
    • Natera Holds Forte in the NIPT Market
    • Invitae Banks on Low Cost Solutions for Expanding Revenues
    • Regulatory Environment
    • Genetic Information Nondiscrimination Act Boosts Genetic Testing
    • Stricter Regulations for DTC Genetic Testing
    • FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
    • Select Genetic Test Reimbursement Codes
    • Market Analytics
    • TABLE 34: USA Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 35: USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 36: USA 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 38: USA Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 39: USA 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • EXHIBIT 6: Number of New Cancer Cases in Canada: 2019
    • Regulatory Scenario
    • Market Analytics
    • TABLE 40: Canada Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 41: Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 42: Canada 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 44: Canada Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 45: Canada 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • Demographics Drive Market Growth
    • DTC Genetic Testing Regulatory Scenario
    • Market Analytics
    • TABLE 46: Japan Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 47: Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 48: Japan 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 50: Japan Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 51: Japan 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • Market Overview
    • China Attracts Domestic and Foreign Players
    • Strong Focus on Genomics
    • Genetic Testing to Reveal Real Talent in Children - A New Popular Application
    • China to Take Lead in Rapidly Growing Asian Genomics Market
    • Market Analytics
    • TABLE 52: China Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 53: China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 54: China 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 56: China Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 57: China 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Aging Population to Drive Demand for Genetic Testing
    • EXHIBIT 7: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
    • Legislations/Regulatory Policies in Select European Countries
    • Legislations Governing Genetic Testing in Select European Countries
    • Rising Cancer Incidence Augurs Well for European Genetic Testing Market
    • EXHIBIT 8: Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • Market Analytics
    • TABLE 58: Europe Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027
    • TABLE 59: Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 60: Europe 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 62: Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 63: Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 65: Europe Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 66: Europe 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 67: France Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 68: France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 69: France 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 70: France Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 71: France Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 72: France 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • Parliamentary Regulations
    • Market Analytics
    • TABLE 73: Germany Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 74: Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 75: Germany 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 76: Germany Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 77: Germany Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 78: Germany 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 79: Italy Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 80: Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 81: Italy 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 82: Italy Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 83: Italy Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 84: Italy 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Principles for DTC Genetic Testing Laid out by HGC
    • Market Analytics
    • TABLE 85: UK Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 86: UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 87: UK 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 88: UK Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 89: UK Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 90: UK 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 92: Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 93: Rest of Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of Europe Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 95: Rest of Europe Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 96: Rest of Europe 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • Healthcare Spending in Asia-Pacific: On the Rise
    • India
    • Australia and New Zealand
    • Market Analytics
    • TABLE 97: Asia-Pacific Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 98: Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 99: Asia-Pacific 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 101: Asia-Pacific Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 102: Asia-Pacific 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • Predictive Screening: Another Growth Area
    • Market Analytics
    • TABLE 103: Rest of World Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 104: Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 105: Rest of World 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 106: Rest of World Current & Future Analysis for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027
    • TABLE 107: Rest of World Historic Review for Genetic Testing by Genetic Testing - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019
    • TABLE 108: Rest of World 15-Year Perspective for Genetic Testing by Genetic Testing - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 249